Unleashing the clinical power of T cells

• Verfasst von: Zimmerman, Zachary [VerfasserIn]
• Verfasst von: Maniar, Tapan [VerfasserIn]
• Verfasst von: Nagorsen, Dirk [VerfasserIn]
• Titel: Unleashing the clinical power of T cells
• Titelzusatz: CD19/CD3 bi-specific T cell engager (BiTE) antibody construct blinatumomab as a potential therapy
• Verf.angabe: Zachary Zimmerman, Tapan Maniar and Dirk Nagorsen
• E-Jahr: 2015
• Jahr: January 2015
• Umfang: 7 S.
• Fussnoten: Gesehen am 19.11.2018 ; Advance access publication 19 September 2014
• Titel Quelle: Enthalten in: International immunology
• Ort Quelle: Oxford : Oxford Univ. Press, 1989
• Jahr Quelle: 2015
• Band/Heft Quelle: 27(2015), 1, Seite 31-37
• ISSN Quelle: 1460-2377
• DOI: doi:10.1093/intimm/dxu089
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1583843736

Abstract

Multi-agent chemotherapy is the standard treatment for most B cell malignancies. Since chemotherapy can be associated with significant toxicity and since relapses resistant to chemotherapy often develop, new therapies are needed. Blinatumomab (AMG 103 or MT103) is a late-stage candidate in clinical development, which belongs to a novel class of antibody constructs termed bi-specific T cell engager antibodies. This antibody construct has dual specificity for CD19 and CD3 and can re-direct polyclonal cytotoxic T lymphocytes toward the tumor. This review focuses on the pre-clinical and clinical development of blinatumomab as a powerful new tool in the treatment of B cell malignancies.